Bishop John E sold $76K of ARDX

Bishop John E (See Remarks) sold 19,750 shares of ARDELYX, INC. (ARDX) at $3.86 across 2 trades on 2026-08-21.

Original reporting
SEC EDGAR · Bishop John E
Published Aug 25, 2026, 11:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Bearish
medium confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXBearishLow
01

Why it matters

The disclosed sale is modest in dollar terms but involves an officer, which may be watched by traders for sentiment cues.

02

Market read

Routine insider sale with limited trading impact.

03

What to watch

Potential upcoming clinical data releases that may offset any negative sentiment from the sale.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-25

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$ARDXBearishMedium confidence
Context

Officer Bishop John E sold 19,750 shares for $76,173 in a Form 4 filing on 2026-08-25.

Expected impact

Potential modest downward pressure on ARDX price.

Evidence & confidence

The sale size is modest ($76K) but involves an officer, which can influence short-term perception.

Market effects

Minimal impact on the biotech sector; typical insider sales are routine.

No regional effect; limited to ARDX shareholders.

Low global relevance.

Counterpoint

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • Bishop John E

    Insider who sold shares.

  • ARDELYX, INC.

    Biotech firm listed under ticker ARDX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.